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1. Introduction 
Cancers of the colon and rectum together are second most common tumor type worldwide. 
The prognosis for the survival after disease progression is usually poor (1). Cancer anorexia-
cachexia syndrome is highly prevalent among patients with colorectal cancer, and has a 
large impact on morbidity and mortality, and on patient quality of life. Early intervention 
with nutritional supplementation has been shown to halt malnutrition, and may improve 
outcome in some patients (2).  
The etiology of cancer-associated malnutrition appears to be related to the pathological loss 
of inhibitory control of catabolic pathways, whose increased activities are not 
counterbalanced by the increased central and peripheral anabolic drive (3).  
The goals of nutritional support in patients with colorectal cancer are to improve nutritional 
status to allow initiation and completion of active anticancer therapies (chemotherapy and 
or radiotherapy) and improve quality of life (3, 4). 
Cancer growth and dissemination but also cancer treatments, including surgery, 
chemotherapy, and radiation therapy, interfere with taste, ingestion, swallowing, and digest 
food which leads to hypophagia. Also, chemotherapy agents may cause nausea and 
diarrhea (3, 4). Although many new agents are on the market to combat these symptoms, 
prevalence of colorectal cancer is still high (1). 
We studied the influence of nutritional support (counseling, nutritional supplements, 
megestrol acetate) on physical status and symptoms in patients with colorectal cancer 
during chemotherapy. The study was designed to investigate whether dietary counseling or 
oral nutrition commercial supplements during chemotherapy and/or BSC affected 
nutritional status and influence survival status prevalence in patients with colorectal cancer. 
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Results: Three hundred and eighty-eight colorectal cancer patients were included in the 
study. Nottingham Screening Tool Questionnaire, Appetite Loss Scale and Karnofsky 
Performance Status were taken to evaluate the nutritive status of patients. Group I consisted 
of 215 patients who were monitored prospectively and were given nutritional support and 
in this group weight gain of 1,5 kg (0,6-2,8 kg) and appetite improvement was observed in 
patients with colorectal cancer. In both groups Karnofsky Performance Status didn’t change 
significantly reflecting the impact of the disease itself.  
Nutritional counseling, supplemental feeding and pharmacological support do temporarily 
stop weight loss and improve appetite, QoL and social life, but this improvement has no 
implications on patients KPS and course of their disease. 
Conclusion: These results encourage further studies with more specific nutritional 
supplementation in patients with colorectal cancer and probably in gastrointestinal 
oncology.  
2. Colorectal cancer 
The incidence and mortality rates for cancers of the colon and rectum are among the highest 
of all malignancies worldwide (1, 2). Colorectal cancer is second in global cancer incidence 
and it is the most common cause of cancer death among non-smokers. US and EU incidence 
figures exceed global averages, which is consistent with an increased risk in industrialized 
nations (2). Factors associated with increased risk of colorectal cancer are host susceptibility 
and a sequence of different carcinogenic exposures. Specific etiology for sporadic colorectal 
cancer is still elusive but predisposing hereditary and environmental factors have been 
clearly identified (5).  
2.1 Etiology of colorectal cancer 
Important causes of colorectal cancers are uncommon genetic syndromes. A small 
percentage of “sporadic” colon cancers cluster in families. Relatives of people with 
colorectal cancer have increased risk for colorectal cancer, and risk varies depending on the 
number of relatives affected and the age at which cancer occurred (5).  
Colorectal cancer is a heterogeneous disease that can develop through only partly known 
complex series of molecular changes. It is a long-term, gradual process which, besides 
external factors (carcinogens), also involves ever more recognized hereditary factors that 
cause genetic changes capable of triggering the uncontrolled mucosal (epithelial) growth (1, 
5). The sequence of events that leads to the development of disease are passage from normal 
mucosa to adenoma – malignantly transformed adenoma and invasive carcinoma is 
associated with a series of genetic events occurring over long periods (5-7 years), the 
knowledge of which keeps expanding for the past ten years (1). In other words, the 
malignant transformation of cells requires various types of genetic damage in the form of 
gene mutation, deletion, amplification or expression disorder (1). In the 1990-ies, Fearon and 
Vogelstein first developed an algorithm for genetic events in colorectal cancer. According to 
their model, sporadic colon cancer arises as a result of a series of genetic changes that affect 
the process progression from enhanced epithelial proliferation to metastatic disease. The 
ultimate outcome of the process depends more on the number of accumulated changes than 
on their chronology.  
The syndromes of colorectal cancer are inherited in an autosomal dominant fashion and are 
categorized by phenotypic, histological and genetic findings. Familial adenomatous 
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polyposis, hereditary nonpolyposis colorectal cancer, Peutz-Jeghers disease, juvenile 
polyposis, Cowden disease are rare conditions (6, 7).  
Ulcerative colitis, among other diseases in the medical history, is the top risk factor. The 
longer the disease and the segment of the colon affected, the higher the risk. The risk is also 
increased in individuals with Crohn’s disease. The patient undergoing surgery for colorectal 
cancer has three times the risk of cancer recurrence (9).  
The inheritance determines individual susceptibility to sporadic cancer but the lifestyle and 
environmental exposures are necessary for cancer expression. Colorectal cancer incidence 
varies between different geographic regions and incidence and mortality rates have been 
highest in developed western nations (10, 11). The basic argument that environment plays a 
huge role in colorectal cancer expression we get from observational studies in migrant 
populations. Migrants from low-incident regions to the high-incident regions of North 
America within one generation accept the incidence of the host country. Yet, studies with 
migrants also suggest that geographic variation in colorectal cancer incidences is due to 
environmental exposures and not due to the inherent predisposition (racial and ethnic 
group) (1, 10, 11). 
Population based investigations have found many dietary and other environmental factors 
associated with colorectal cancer incidence (2). Most of these studies have methodologic 
limitations and therefore the interpretation of such studies has to be made with caution. 
Many studies have been conducted to investigate external factors that may increase or 
diminish the incidence of colorectal cancer. Many authors recognize four risk factor 
categories: epidemiological, intestinal, dietetic and mixed. The most frequently reported 
factors, among these shown to increase the risk of developing the disease, are diets rich in 
meat and animal fats (bile salts), physical inactivity, smoking and alcohol consumption (1, 2, 
12). Between other diets ingested, consumption of red meat has the strongest correlation 
with colorectal cancer; over 30 case control studies report increased risk of colorectal cancer 
with higher red meat intake. Especially fried, barbecued and well-done meat is associated 
with colorectal cancer risk. Obesity and high caloric intake are the independent risk factors 
for colorectal cancer, excessive body mass gives a two fold increase in colorectal cancer, and 
this association in more expressed in men than women (12). Although studies carried out in 
humans and animal models have shown a positive correlation between the saturated 
fats/red meat consumption and the development of colorectal cancer, only a few of them 
are confirmed to be statistically significant. The total amount of fat in terms of daily caloric 
intake (>40%) and their form appears to have special significance. The conversion of dietary 
phospholipids to diacylglycerol by intestinal bacteria is assumed to be a potential 
mechanism of carcinogenesis. Diacylglycerol can enter the epithelial cell directly and by 
stimulating protein kinase C, it evokes intracellular signal transduction or mucosal 
proliferation. Another important mechanism is the formation of free radicals during fat 
metabolism and the mucosal damage induced by the secondary bile acids (lithocholic acid). 
Nitroso compounds, heat-generated heterocyclic amines and high protein intake 
(accelerated epithelial proliferation) have potential carcinogenic consequencies (12, 13). 
Among the factors mentioned to reduce the risk are diet high in plant fibers and calcium, 
antioxidants (vitamin E, selenium etc.), menopausal hormone replacement therapy and 
administration of nonsteroidal anti-inflammatory drugs (12). In 1990 more than 13 studies 
showed significant reductions in colorectal cancer risk comparing the group with higher vs 
group with lower fibre intake. Some of the potential benefit mechanisms are: increased stool 
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weight, dilution of potential carcinogens and increased colon transit rate. But other studies 
did not confirm such results, and today in this field we have inconclusive and controversial 
results (12, 13). 
A complex interaction between inherited predispositions and external factors is responsible 
for the development of colorectal cancer (Table 1).  
 
RISK FACTORS FOR COLORECTAL CANCER 
Genetic factors 
- inherited polyposis syndrome 
- syndromes: Gardner, Turcot 
- Peutz-Jeghers, juvenile polyposis 
Family factors 
- inherited colorectal cancer syndrome 
- hereditary adenocarcinomatosis syndrome 
- family history of colorectal cancer 
Pre-existing 
diseases 
- ulcerative colitis,  Crohn’s disease 
- colorectal cancer 
- radiation therapy to the small pelvis 
- colorectal polyps 
External factors 
- diet rich in meat and animal fat 
- physical activity 
- smoking 
Other 
factors 
- age over 40 years 
Table 1. Risk factors for colorectal cancer development  
2.2 Pathology 
Molecular basis of disease are genetic mutations of somatic cells and the inner innervation of 
the colon is important in carcinoma pathogenesis and spread. According to their 
macroscopic appearance, colorectal cancers are divided into exophytic, ulcerative and 
stenosing tumors. Exophytic tumors are most often located in the right half of the colon, 
while stenosing tumors are mostly found in its left half. The majority (up to 75%) of 
colorectal cancer occur within the descending colon, sigmoid colon and rectum, 15% of cases 
are located in the cecum and ascending colon, and only 10% in the transverse colon (13, 14, 
15). Adenocarcinoma accounts for more than 95% of colorectal cancer cases. The prognosis 
of the disease is associated with the depth of tumor invasion through the colonic wall, 
peripheral lymph node involvement and absence or presence of distant metastases. The 
Dukes staging system (Table 2) as used in clinical practice divides this cancer into three 
stages, depending on the depth of cancer invasion into the colorectal wall (16, 17).  
 
DUKES A - tumor confined within the colorectal wall 
DUKES B - tumor invaded through the colorectal wall  
        B1-tumor limited to muscular mucosa 
        B2-tumor protruding in/trough serosa 
DUKES C - metastases to lymph nodes  
Table 2. The Dukes staging system for colorectal cancer   
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2.3 Clinical signs and diagnostic procedures 
The symptoms of colorectal carcinoma depend on the anatomical location and size of the 
tumor. The tumor located in the cecoascendent portion will not necessarily produce 
obstruction since in this portion the stool has a liquid consistency, and the colonic lumen is 
wider than in the other parts. Patients complain of weakness, subfebrile temperature and 
blunt pain in the right lower hemiabdomen, and their laboratory tests show a high 
sedimentation rate and sideropenic anemia (1, 13).  
Tumors of the transverse colon and on the left side of the half usually invade the colonic 
wall in a ring-shaped pattern mainly producing symptoms of the obstructive nature 
(cramping pain after meal, meteorism, change in stool form, occasional sudden ileus 
development and even bowel perforation). Symptoms of tumors confined to the 
rectosigmoid portion are most often false and/or painful urge to defecate (tenesmus), 
narrow stool and hematochezia (13).  
The patient with suspicion of colorectal cancer should undergo a complete physical 
examination which must include digital rectal examination. In a large number of patients, 
the digital rectal examination already shows a hard lump inside the rectum, bleeding on 
touch. Colonoscopy is a procedure for visualizing colonic mucosa and obtaining samples for 
pathohistological analysis. Colonoscopy is the gold standard for detecting colorectal cancer. 
If for technical difficulties colonoscopy cannot be done, double-contrast irrigography may be 
considered although only 70-80% of lesions are detected by this method. Virtual 
colonoscopy and MR colonoscopy are also more and more often used. These radiology 
techniques use high-speed spiral CT and magnetic resonance imaging, and sophisticated 
software to process endoluminal images of the air-filled colon. Diagnostic techniques show a 
sensitivity of about 90% for tumors larger than 10 mm. Disadvantage is an inability to take 
biopsy samples and perform interventions available during colonoscopy. ‘Colon capsule’ for 
minutely detailed inspection of the colonic mucosa is also being gradually introduced, 
although this technique has the same disadvantage as the above mentioned techniques, and 
that is its inability to obtain biopsy samples (1, 13). Endoscopic ultrasound of the lower 
digestive tract is capable of providing assessment of tumor invasion into muscles and 
adjacent structures, as well as assessment of regional lymph node enlargement. The 
technique is employed to determine the extent of the spread of rectal tumors. Diagnosis of 
the spread of the disease involves imaging techniques (US, CT/MSCT/MRI of the abdomen 
and small pelvis, and CT/MSCT of the thorax). Serum CEA has limitations in sensitivity 
and specificity but was recommended for detection of recurrence. Molecular detection of 
tumor cells in circulation may prove to be more sensitive and specific than CEA (13, 18). 
2.4 Treatment 
Treatment for colorectal cancer depends on the extent of cancer spread. Surgery is the 
method of choice for treatment of localized tumors. Colon resection surgery for colorectal 
cancer must be as radical as possible. Chemotherapy, immunotherapy and radiotherapy 
used may be adjuvant, neo-adjuvant, curative or palliative in nature. Adjuvant 
chemotherapy aims to destroy micrometastases following surgery, and neo-adjuvant 
chemotherapy is aimed at reducing the tumor mass to allow surgery for either the primary 
tumor or distant metastases (usually to the liver or lungs) (1, 13). Systemic therapy for 
disseminated disease has been gaining popularity over the past few years. Treatment 
options for colorectal cancer include a variety of chemotherapy and immunotherapy 
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regimens, with 5-fluorouracil/leucovorin, which may be added irinotecan and/or 
oxaliplatin, and bevacizumab, cetuximab and panitumumab as biological therapy, still 
remaining the mainstay for the management of patients with disseminated disease (3). The 
addition of this molecularly targeted therapy to standard chemotherapy improves treatment 
response, prolongs both the time to disease progression and eventually, median survival for 
disseminated or metastatic colorectal cancer, which currently is over 30 months (3, 19). In 
the future, prognostic and predictive factors will allow individual identification of patients 
who may benefit most from adjuvant chemotherapy, and which therapy should be used for 
the treatment of disseminated disease (personalized medicine). Therapy of rectal cancer 
includes adjuvant chemotherapy combined with radiation therapy (19).  
Despite huge advances in diagnostic and surgery and despite global and national programs 
of prevention, about 50% of colorectal carcinomas are diagnosed in advanced stage (11). 
Advanced disease is largely refractory to conventional therapy and 5 years survival is still 
poor. Patients with advanced disease suffer from many stress symptoms (pain, vomiting, 
diarrhea, anorexia-cachexia syndrome, and etc.) and the therapeutic goal for them is 
maintenance of quality of life (QoL) (13). Many of those symptoms have implications for 
diagnostic and therapeutic procedures and can heavily disturb the process of chemo-
immunotherapy and radiotherapy (3).  
3. Anorexia-cachexia syndrome 
3.1 Pathophysiology of anorexia-cachexia syndrome 
Anorexia is defined as an unintentional reduction in food intake and anticipated cachexia. 
Cachexia develops as a result of progressive wasting of skeletal muscle mass and to a lesser 
extent adipose tissue (20). In cachexia, progressive wasting of skeletal muscle mass is 
replaced with adipose tissue and this occurs even before weight loss. Anorexia-cachexia 
syndrome is highly prevalent among patients with malignant diseases. Depending on 
primary tumor site anorexia-cachexia syndrome is present in 8-88% of cancer patients. 
Tumors of head and neck, stomach and pancreas have highest percentage of cachexia (21). 
At the time of diagnosis weight loss is present in about 50% of patients. Weight loss is 
independent predictive factor of survival (21). Cachexia-anorexia syndrome includes clinical 
features which are associated with growth of cancer. In addition, it has a large impact on 
morbidity, mortality and on patients’ quality of life. Cancer cachexia develops in a majority 
of patients with advanced disease (22) (70 %) and directly causes death in 20% of cancer 
patients. Clinical signs of cancer cachexia are anorexia and weight loss. Abnormalities in 
carbohydrates, fat, protein and energy metabolism are clinically manifested as weakness, 
fatigue, malaise, loss of skeletal muscle and adipose tissue. In serum chemistry and 
haematology tests we can find anaemia, hypertrigliceridaemia, hypoproteinaemia with low 
albumines, hyperlacticacidaemia and glucose intolerance (insulin resistence) (23). Metabolic 
aberration in cancer cells and cells and microenvironment (inadequate energy intake, 
increased energy expenditure, mucositis, nausea, vomiting, change in taste or psychological 
problems as reaction to cancer disease) cause primary cancer cachexia. There are several 
conditions that can contribute decreased food intake (gastrointestinal obstruction, post-
chemotherapy nausea and vomiting, pain and etc) and cause secondary cancer cachexia (24, 
25). Anorexia-cachexia syndrome often occurs or worsens after the administration of 
chemotherapy. Chemotherapeutic agents are toxic to malignant tissue, and also to the 
quickly proliferating cells. This group of cells also includes cells of the gastrointestinal 
www.intechopen.com
 
Effects of Dietary Counseling on Patients with Colorectal Cancer 
 
217 
mucosa. Consequently, the absorption of nutrients is reduced. Some chemotherapeutics may 
affect the digestive system causing severe nausea, vomiting, abdominal pain, stomatitis and 
aversion to food. It should be noted that, in addition to the above mechanism for 
development of this syndrome, some chemotherapeutic agents also affect the taste buds of 
the tongue resulting in a changed and reduced sense of taste. It may also lead to reduced 
saliva production (26). 
Sometimes we cannot find a reason for anorexia and weight loss may be unrelated to 
nutritional intake. In this cases weight loss is reflection of elevated resting energy 
expenditures and over expression of pro-inflammatory cytokines (27). The most common 
factors to stimulate the production of proinflammatory cytokines include: TNF-alpha, 
interleukins, interferon gamma and leukemia inhibitory factor. It should be noted that, due 
to such complex mechanism, energy supplementation in cachectic patients does not result in 
an increased body mass index (28).  
The pathophysiologic mechanism is correlated with the production of catabolic factors 
either by the tumor or via factors produced by the host. Cancer cachexia differ from 
starvation. It is an unquestionable fact today that cancer cachexia is pro-inflammatory 
condition. The pathophysiology of cachexia involves very complex pathways; cachexia is 
caused with numerous metabolic changes mediated with pro-inflammatory cytokines. The 
most known mediators are tumor necrosis factor α, interleukin-1 (IL-1), interleukin 6 (IL-6), 
interferon-Ƴ (from patients mononuclears) and molecules from tumor cells as lipid 
mobilisation factor (LMF) and proteolysis inducing factor (PIF). PIF is stimulating 
adenosine-triphosphate ubiquitin proteolitic pathway that is important in degradation of 
muscle mass and its stimulating synthesis of C-reactive protein (28, 29). 
The result of these changes is impairment of immune functions, quality of life, and 
performance status. The worst consequence is inability of patient to endure chemo, 
immunotherapy and radiotherapy. Cachexia decreases response to therapy due to frequent 
toxicity and severe complications, what leads to shortened survival time (3, 20).  
3.2 Nutritional support 
Although increasing nutritional intake is insufficient to prevent the development of 
cachexia, nutritional support (taking into account the specific needs of the patient group), is 
required to reduce the consequences of nutritional decline and to improve quality of life and 
possibility to support the anticancer therapy (30). However, data from published studies are 
divided; some studies suggest that aggressive nutritional support can improve response to 
the antitumor treatment and decrease complications, but some deny any impact of 
nutritional support on tumor response, chemotherapy toxicity and survival (3, 30). 
Aggressive nutritional therapy does not significantly influence the outcome of patients with 
advanced cancer; „super“nutrition alone cannot reverse cachexia. But its use is still 
warranted because the patients QoL is significantly improved (3). The pharmacological 
treatments of cachexia antagonize the main symptoms (anorexia and chronic nausea) and 
improve the muscle metabolism. A significant number of studies (many uncontrolled) have 
suggested that anorexia and asthenia can be alleviated in cancer patient under corticosteroid 
treatment; also, the feeling of well-being is observed (31).  
We must not underestimate advantage of nutritional treatment in improvement of asthenia 
and patients body image. Oral nutrition (after nutritional counseling) is ideal for cancer 
patients with a functional bowel. Enteral nutrition is useful in patients with advanced head 
and neck cancers or esophageal and gastric cancer and the use of parenteral nutrition (due 
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to high costs and morbidity of 15%) with exception of high selected cases has no major role 
in care of cancer patients, especially in terminal disease (30, 31). In patients with colorectal 
cancer, enteral nutrition is usually provided by administration of food and/or commercial 
nutrient solutions and formulas (32). They either supplement daily diet or provide basic 
nutritional needs to patients who are unable to ingest sufficient amounts of food. The 
baseline requirements to administer such feeding include preserved swallowing function 
and the ability of the esophagus and stomach. There is a wide range of enteral nutrition 
formulas available for everyday use (33). Enteral nutrition formulas are classified into the 
following categories: monomeric (elementary) formulas, oligomeric formulas, polymeric 
formulas (32, 34, 35). The essential difference between them is in their size and/or the 
amount and type of molecules present. Accordingly, formulas containing a larger number of 
molecules that are also shorter at the same time, have a higher osmolality and can therefore 
cause side effects, such as diarrhea. The osmolality of an enteral formula depends on the 
type and amount of carbohydrates. Polysaccharides account for the vast majority of 
carbohydrate types present in the enteral feeding formulas. According to their solubility, 
fibers in the digestive system are divided into two categories: soluble and insoluble. Soluble 
fiber absorbs water in the intestinal lumen and increase the volume of the stool. They thus 
help regulate bowel motility. Soluble fibers are fermented by bowel bacteria using the 
aerobic pathway. Pectin slows down the emptying of the stomach and prolongs the passage 
of contents through the colon resulting in formation of the stool of satisfactory consistency 
even in tube fed patients (37). Normal metabolism requires daily protein intake of 0.8-1.0 
g/kg body weight, and in the hypercatabolic state daily protein needs range from 1.2 to 1.6 
g/kg body weight. According to the presence of nitrogen-containing compounds the diet 
may be divided into three groups: polymeric diet (includes natural proteins), oligomeric diet 
(includes small peptides), elementary diet (containing amino acids). Patients with the 
preserved gastrointestinal function require a diet in which complete proteins prevail (38). In 
case of compromised digestion, peptides should be the most represented. Among the amino 
acids, glutamine should be singled out. Glutamine helps maintain normal intestinal 
integrity by stimulating RNA, DNA and protein synthesis, resulting in an increase in the 
number and size of intestinal villi. Glutamine also prevents damage to intestinal 
permeability, preserves mucosal structure and prevents translocation of bacteria and toxins 
in the intestine. Glutamine is an important nutritional substrate for the intestinal cell line. In 
catabolic conditions including colorectal cancer, the intestinal system’s requirements for 
glutamine are increased. The deficiency can be compensated for by addition of glutamine to 
the enteral nutrition formula (39). Arginine is another amino acid that plays a significant 
role in the immune events. It stimulates nitrogen oxide (NO) synthesis and the CD4/CD8 
ratio, as well as the release of insulin, glucagon, prolactin and somatostatin (40, 41). The use 
of arginine requires caution as increased NO synthesis may accelerate the synthesis of 
proinflammatory cytokines and thereby cause a number of side effects. The main role of 
lipids in enteral formulas is to ensure large amounts of energy stored in relatively small 
volumes and sufficient amount of essential fatty acids which are a vital component of cell 
membranes and organelles. Corn oil and soybean oil used in enteral formulas provide long-
chain triglycerides (LCT), while coconut and palm oil provide medium-chain triglycerides 
(MCT). These products have a favorable effect on: 1) growth, differentiation and function of 
lymphocytes, macrophages and granulocytes; 2) release of trophic hormones or growth 
factors; 3) function of NK cells; 4) IL-2 synthesis; 5) improvement of mesenteric blood flow; 
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6) reduction of skeletal and visceral muscle proteolysis; 7) prevention of bacterial 
translocation; 8) reduction in the frequency and severity of infectious complications and 9) 
shortening hospital stay (42). Fatty acids are thus formed providing a basic substrate for the 
colonic mucosa. Formulas containing omega-3 fatty acids from fish oil have been recently 
introduced. Omega-3 fatty acids reduce the synthesis of immunosuppressive and 
proinflammatory mediators. Meta-analyses of several studies have shown that 
immunomodulatory formulas do not significantly reduce mortality compared with standard 
enteral formulas. Their administration, however, achieves a lower rate of infection and 
septic complications, reduces dependency on assisted ventilation and shortens length of 
hospital treatment (43). 
Omega-3 polyunsaturated fatty acid, eicosapentaenoic acid (EPA) can down-regulate the 
production of pro-inflammatory cytokines such as IL-6, IL-1 and TNF in patients with 
cancer and in healthy individuals. EPA can also inhibit the effects of proteolysis inducing 
factor (PIF). EPA normalizes metabolic pathways changed due to malignant disease and 
stabilize weight gain through the competitive metabolism with arachidonic acid. EPA 
metabolites have lower inflammatory and immunosuppressive effect versus arachidonic 
acid metabolites. Especially interestingly is inhibitory effect of EPA on pancreatic and 
colorectal cancer cell line growth observed „in vitro“ (44, 45). Wigmor and Bruera, like many 
other investigators, showed that EPA can stabilize body weight in cancer patients (46). We 
investigated if dietary counseling and oral nutrition supplement during chemotherapy 
affected nutritional status and symptom prevalence in our first study on 388 patients with 
colorectal cancer receiving chemotherapy for advanced disease (FOLFIRI/XELIRI/ 
FOLFOX) (47, 48). 
Megestrol acetate is a type of medicine that comes in suspension form recommended in 
treatment guidelines for appetite and body weight loss in patients with malignant diseases. 
The drug belongs to a group of steroid hormones - progesterone. Its empirical formula is 
C24H32O4. Progestational derivate megestrol acetate has been evaluated in many studies; 
conclusion is that megestrol acetate significantly increases appetite, caloric intake and 
nutritional status with mild side effects as edema and hypercalcaemia. It is not completely 
clear through which mechanisms megestrol is acting. It is assumed that megestrol acetate 
changes the cytokines which are inhibiting TNF effects. Stimulation of appetite is due to 
stimulation neuropeptide Y in lateral hypothalamus. Megestrol acetate enhances appetite 
and increases food intake, enables the administration of specific treatments, and improves 
both patient treatment tolerance and their quality of life. Implementation of megestrol 
acetate in nutritional support plan is necessary; according to the highlights of the 2004 
Cachexia Cancer Conference anorexia preceding to weight loss and orexigenics are 
necessary even when weight loss is absent. Furthermore, patients with cancer cachexia do 
not react on isolated over caloric food intake. Mild side effects (edema) are not enough 
pronounced over the social benefits caused by appetite stimulation; patients do not 
withdraw megestrol acetate therapy (49). Therefore, the International Association for 
Hospice and Palliative Care, NCCN Guidellines and European Palliative Care Research 
Collaborative Group recommend megestrol acetate as a mandatory drug for treatment 
cancer cachexia (50). The recommended starting dose is 400 mg (10 ml) once a day. The dose 
may be increased up to 800 mg (20 ml) / day. The most common side effects of megestrol 
acetate include edemas, insomnia, impaired libido, and very rarely thromboembolic 
complications (48, 50). 
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The choice of enteral route depends on the underlying pathology, anticipated duration of 
enteral feeding and patient’s preferences (30). In addition to the oral route of nutrition 
administration the transnasal route can also be considered. Indications for transnasal tube 
feeding include conditions or illnesses where normal feeding cannot be provided, and 
where the gastrointestinal tract maintains its function. For this purpose, nasogastric, 
nasoduodenal and nasojejunal types of tubes may be used. The tubes are usually placed 
‘blindly’, however they may be placed by radiological and endoscopic means. The tubes are 
used when it is anticipated that tube feeding will be needed for up to 4 weeks. If enteral 
feeding is likely to be needed for more than 4 weeks, percutaneous endoscopic gastrostomy 
tubes or percutaneous endoscopic jejunostomies may be placed via an endoscopic access. 
The surgical placement of the gastrostomy or jejunostomy tube may also be taken into 
consideration. Two types of feeding can be used for patients requiring tube feeding: bolus (6 
to 10 doses a day, each ranging from 50 to 200 ml, given over 5 to 30 minutes) or continuous 
feeding( 20 to 150 ml per hour during 16-18 hours). The method of ‘bolus feeding’ is more 
frequently reported to cause side effects than continuous feedings (30, 35). 
In some clinical situations, enteral feeding may be unsafe or contraindicated. Reasons for 
postponing enteral nutrition administration are as follows: persistent nausea/vomiting, 
intensive postprandial pain, diarrhea, mechanical obstruction, diminished bowel motility, 
malabsorption, gastrointestinal bleeding. In mentioned situations, parenteral feeding is 
used. Parenteral feeding may be administered by peripheral or central vein access. Risk-
benefit assessment of parenteral nutrition is necessary for each patient (30, 31, 35). 
We can evaluate nutritional status of the cancer patient with quick screening methods (NRS-
2002, NSTQ, ect) or more detailed examination (laboratory findings, anthropometric 
measurement, body composition measurement, BMI). Nottingham Screening Tool 
Questionnaire is simple, quick, and proper for re-evaluating. Another simple model 
(Fearon) is suggested for quick evaluation: if patient unintentionally decrease in weight gain 
more than 5% in 3 to 6 months, if caloric intake is less than 1500 kcal/day and C-reactive 
protein value is 10 and higher. Based on these data we can assume that cancer cachexia is 
developing (34, 35, 36, 43, 46, 50) 
3.3 Study results 
Our study was conducted at the Gastrointestinal Oncology Department, Clinic for 
Internal Medicine, University Hospital Center Rijeka, from January 2001 to December 
2007. The aim of the study was to evaluate the effect of nutritional support in patients 
with colorectal cancer. The follow-up included 338 patients divided into two groups. 
Group I: patients receiving nutritional support (215 patients), and group II patients who 
did not receive nutritional support (173 patients); retrospectively collected data. Visit 0 
took place one week before initiation of chemotherapy. The nutritional status was 
evaluated according to body weight change. The body mass index (BMI) was calculated 
for all patients and all patients were also evaluated through three questionnaires: 
Nottingham Screening Tool (Table 3), Appetite Loss Scale and Karnofsky Performance 
Status. The reassessments were done at control visits, each visit taking place before the 
next chemotherapy course. There were, in total, 12 visits performed. The aim of the study 
was to assess the effects of nutritional support in colorectal cancer patients on 
chemotherapy. For all patients, the following parameters were monitored and statistically 
evaluated: selection of nutritional support regimen in group I, BMI in groups I and II, at 
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visit 0 and visit 12, Nottingham Screening Tool Questionnaire in groups I and II, at visit 0 
and visit 12, Appetite Loss Scale in groups I and II, at visit 0 and visit 1, Weight loss in 
groups I and II , at visit 0 and visit 12, Karnofsky Performance Status in groups I and II, at 
visit 0 and visit 12, side effects of megestrol acetate. Evaluating the initial risk 
measurement according to BMI, decrease in weight gain and NST, we did not find any 
significant difference between the two groups. We performed 12 visits in follow-up 
according to chemotherapy schedule. Before initiation of chemotherapy, we re-evaluated 
nutritional status of our patients using evaluation tools. After chemotherapy was 
completed, in group I (consisted of 215 patients who were monitored prospectively and 
were given nutritional support) we observed weight gain of 1.5 kg (0.6-2.8 kg) and 
appetite improvement, the most commonly seen result after 4 weeks of therapy with 
megestrol acetate. The appetite also improved on Appetite Loss Scale from 3.1 (pre-
chemotherapy) to 4.7 (post-chemotherapy). But KPS did not change significantly (74.2% 
before chemo versus 80.4% after chemo respectively) reflecting the impact of the disease 
itself. The most common side effects in patients receiving enteral nutrition were diarrhea 
(12% of patients) , abdominal pain (9%) and altered taste sensation(5%). The most 
frequently reported side effect in patients receiving megestrol acetate was the occurrence 
of edema (20% of patients). 
This clinical study is ongoing and preliminary results from more than 600 patients are 
similar to this one.  
 
BMI Score 
>20 0 
18-20 1 
<18 2 
 
Has the patient unintentionally lost weight 
during last 3 months? 
Score 
No 0 
A little, up to 3 kg 1 
A lot, more than 3 kg 2 
Table 3. Nottingham Screening Tool Questionnaire 
Score:  0-2 Patient is not in nutritive risk and does not need nutritional support 
  3-4 Patient need re-evaluation weekly 
  ≥ 5 Patient is in nutritive risk and needs nutritive support  
4. Discussion 
Anorexia-cachexia syndrome often occurs in patients with gastrointestinal cancers. 
Malnutrition has huge impact on outcome in patients who underwent major surgical 
resections, and also in patients who have chemo/radiotherapy treatment (3, 22). 
Although manifestations of chemotherapy injury on nutritional status is well-known, the 
potential role of nutritional supplementing is still not explored in detail. When treating 
cancer patients with chemotherapy we observed two problems and one of them is general 
failure in recognition of the weight loss early enough to perform nutritional support (30). 
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But if we know that patients will undergo to stress-full procedure which can have impact on 
his nutritional status (diagnostic procedures, colonoscopy for example, major 
gastrointestinal surgery) we have to give adequate nutritional support according to different 
clinical algorithms (3). 
Adequate substitution with metabolites, increased caloric intake, inhibition of catabolic and 
inflammatory mediators leads to decrease of surgery, chemo and radiotherapy 
complications, but still has no significant impact on survival. Nutritional counseling, 
supplemental feeding and pharmacological support do temporarily stop weight loss and 
improve appetite, QoL and social life but this improvement has no implications on patient´s 
KPS and course of their disease. An improved knowledge of the pathophysiology of cancer 
induced cachexia will lead to development of more effective treatments (26). 
In clinical practice, the role of nutrition therapy is often assumed to be less important than 
role of chemo, immunotherapy and radiotherapy as outcomes are less clear in literature (22, 
26, 30). Our study showed that early nutritional intervention can decrease course of weight 
deterioration in the early course or locally advanced or metastatic colorectal cancer. 
Karnofsky Performance Status did not change significantly, what we expected.  
Taking food is not only a physiologic necessity, but also cultural and a social event reflecting 
life and religious philosophy. Nutritive support can facilitate life of oncology patienta, their 
family support and caregivers understand (1). Therefore we have to recognize nutrition-
related issues and to implement strategies that will lead to a better outcome for patient and 
his caregivers. In the end of the life the wish of dying patient is most important factor 
regarding enteral/parenteral nutrition. The interaction between major syndromes in 
terminal disease (pain, cachexia, cognitive failure) should be better established because it 
seems that severity of them has impact on the others. If we improve pain and depression we 
can expect impact on cachexia syndrome (3, 21). 
5. Conclusion 
The role of nutritional therapy in oncology patients has been neglected. This mainly results 
from failure to recognize malnutrition and untimely introduction of nutritional support. 
Our study shows that early introduction of nutritional support can decrease weight loss and 
in some cases even enable weight gain in patients with locally advanced and metastatic 
colorectal cancer. 
To achieve better treatment results for patients with colorectal cancer, nutritional therapy 
should be considered as a highly important part of their treatment and more attention 
should be paid to timely recognition of malnutrition and introduction of nutritional support. 
Patients with anorexia-cachexia syndrome should undergo to individualized nutritional 
intervention where nutrition counseling is base for improvement of nutritional status, 
quality of life and social life. Anorectic patients have changes in taste and smell and do not 
support high-fat food and therefore frequent but small meals are highly recommended (20). 
Future perspectives:  
Cancer patients have increased level of growth hormone (GH), low serum concentrations of 
insulin growth factor-1 (IGF-1) and insulin resistence. Loss of lean mass and inflammatory 
processes are closely connected to the action of three signaling molecules: insulin, growth 
hormone and insulin growth factor-1 is essential (51). Basic stimuli of insulin, IGF-1 and GH 
does not provide response in muscle cells in cachexia, its reasonable to target post-receptor 
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pathways or using alternative pathways in muscle cells. A number of molecules exhibiting 
anti cytokines activity have been tested without significant clinical data (20). Ghrelin is a 
hormone that stimulates the release of GH and increases appetite. In a phase II clinical 
study, ghrelin agonist anamorelin produced an improvement in total body mass (52).  
Despite cachexia is very common condition in cancers, there are still very few trials of drug 
therapies to reduce weight loss in cancer cachexia. Cachexia remains poorly studied and 
often undertreated condition that causes severe impairment of quality of life and increases 
mortality.  
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